Alto Neuroscience, Inc. (ANRO) Stock Price & Analysis
Alto Neuroscience, Inc. (ANRO) closed at USD 22.2 on Thursday, October 22, 2026, down 4.80% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 23.32; the Oct 22, 2026 session ranged USD 22.18–24.29 on volume of 510,809 shares. Market capitalization is $871.17M, with a 52-week range of USD 10.18–37.48 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ANRO.md
Key facts (ANRO)
- Analysts: Buy (mean 2.09 on a 1–5 scale) (11 analysts), mean target USD 38.88 (range 26–60).
- Total return with dividends: 1Y +98.6% vs S&P 500 +14.9%; 5Y +7.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD -0.7, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ANRO)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Operating income | -$37.8M | -$68.6M | -$66.4M | -$88.3M |
| Net income | -$36.3M | -$61.4M | -$63.2M | -$84.2M |
| EPS (diluted) | -$9.73 | -$2.50 | -$2.19 | — |
| Free cash flow | -$33.9M | -$49.5M | -$51.8M | -$68.8M |
| Cash + short-term investments | $82.5M | $168M | $176M | — |
| Total debt | $9.9M | $10.3M | $16.8M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ANRO)
P/B 4.0x · FCF yield -7.90% · Earnings yield -9.67% · Net cash $228M · EV $644M
Analysts (ANRO)
Consensus Buy (mean 2.09 on a 1–5 scale), 11 analysts; mean target USD 38.88 (low 26, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | HC Wainwright & Co. | Target raised | Buy | $55 → $60 |
| 2026-08-17 | HC Wainwright & Co. | Target raised | Buy | $50 → $55 |
| 2026-08-13 | Wedbush | Target raised | Neutral | $24 → $26 |
| 2026-08-13 | BTIG | Target raised | Buy | $28 → $37 |
Total return (dividends reinvested) (ANRO)
| 1Y (from 2025-10-23) | 5Y (from 2024-01-29) | |
|---|---|---|
| Total return | +98.6% | +7.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +99.0% | +2.6% |
| Volatility (annualized) | 78.9% | 117.1% |
| Max drawdown | -40.8% (Sep 2026→Oct 2026) | -91.3% (Jan 2024→Mar 2025) |
Companies that name ANRO in their SEC reports
| Relationship to ANRO | Company | Filing | Sentence |
|---|---|---|---|
| partner | Avalo Therapeutics, Inc. (AVTX) | 10-K Mar 23, 2026 | “Under the out-license agreement, the Company received a mid-six digit upfront payment from Alto, which we recognized as license revenue in 2021.” |
ANRO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.70 | $-0.80 | -11.8% | $0 | 7 |
| Next quarter (ends Dec 2026) | $-0.73 | $-0.78 | -6.6% | $0 | 7 |
| Current fiscal year (ends Dec 2026) | $-2.92 | $-3.15 | -7.1% | $0 | 6 |
| Next fiscal year (ends Dec 2027) | $-3.19 | $-3.43 | -7.2% | $0 | 7 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 22.2 |
|---|---|
| Change | ▼ 4.80% (down) |
| Previous Close | USD 23.32 |
| Open | USD 22.7 |
| Day Range | USD 22.18 – 24.29 |
| 52-Week Range | USD 10.18 – 37.48 |
| Volume | 510,809 shares |
| Market Cap | $871.17M |
| Exchange | NYQ |
Technical Analysis (ANRO)
Nexqual's technical model rates ANRO "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.31 (neutral) |
| vs SMA50 | Below (USD 29.57) |
| MACD | -1.8 (negative) |
Analyst Ratings (ANRO)
Wall Street analysts rate ANRO "Buy" based on 11 analysts, with a mean price target of USD 38.88 (range USD 26–60), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 38.88 |
| High Target | USD 60 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (ANRO)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.7 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.65 vs est -0.77 ▲ beat |
| 2026-03-31 | USD -0.8 vs est -0.51 ▼ miss |
| 2025-12-31 | USD -0.45 vs est -0.51 ▲ beat |
| 2025-09-30 | USD -0.52 vs est -0.64 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (ANRO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -49.17% |
| Debt / Equity | 0.11 |
| Current Ratio | 14.85 |
| Total Cash | $243.73M |
| Total Debt | $23.29M |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (ANRO)
Nexqual rates Alto Neuroscience, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $244M cash and investments vs $16M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$52M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -49%, ROA -26.8% |
Ownership (ANRO)
| Insider Ownership | +4.21% |
|---|---|
| Institutional Ownership | +87.11% |
| Shares Outstanding | 39.24M |
| Float | 29.59M |
| Short % of Float | +13.91% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (ANRO)
Alto Neuroscience, Inc. is led by Amit Etkin, Founder, CEO & Chairman of the Board, per Nexqual as of October 23, 2026 at 10:11 UTC.
| Founder, CEO & Chairman of the Board | Amit Etkin |
|---|---|
| CFO & President | Nicholas C. Smith |
| Chief Operating Officer | Michael C. Hanley |
Major Backers & Investors (ANRO)
Notable institutional backers of Alto Neuroscience, Inc. include Alpha Wave Global, LP, Commodore Capital Lp, Perceptive Advisors Llc, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Alpha Wave Global, LP | 9.45% |
| Commodore Capital Lp | 6.94% |
| Perceptive Advisors Llc | 4.1% |
| Adage Capital Partners GP L.L.C. | 4.08% |
| Spruce Street Capital LP | 3.45% |
| Vivo Capital, LLC | 3.08% |
| Franklin Resources, Inc. | 2.58% |
| Armistice Capital, LLC | 2.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.4% |
| Vanguard Group | 3.54% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt